+ Filter
Loading...
E2
Anti-E2 Recombinant Antibody Products
- Human Anti-HCV E2 Recombinant Antibody (AP33) (TAB-020CT)
-
- Derivation: Phage display library
- Species Reactivity: genotypes 1-6 of HCV
- Type: Human antibody
- Application: ELISA, IP, Neut, FC, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47F) (TAB-238CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47W) (TAB-239CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47F) (TAB-238CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47W) (TAB-239CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47F) (TAB-238CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47W) (TAB-239CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
More Infomation
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Advances in treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) have led to high cure rates of treated patients. Although rates of sustained virologic response of approximately 95% have been achieved, a large number of patients still fail treatment, even with drug combination regiments. A high percentage of these treatment failures are due to the emergence of resistance-associated variants (RAV). Chronic HCV infection consequently will continue as a leading cause of cirrhosis and hepatocellular carcinoma, which are major indications for liver transplantation.
